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66.3% with C virus genotype 1, 65.0% with hepatic cirrhosis 
(94.2% of which Child-Pugh A), and 46.3% under current an-
tiviral treatment. For CLDQ internal consistency, Cronbach’s 
α was 0.88; for construct validity, correlations ranged from 
0.36 to 0.80 ( p < 0.01). Mean CLDQ scores ranged from 4.25 
(Worry) to 5.78 (Abdominal Symptoms). Lower scores were 
observed for Worry, Fatigue, and Emotional Function do-
mains. Statistically significant differences were found in me-
dian values of Worry (CLDQ) and Role Emotional (SF-12) ( p < 
0.05) for “current antiviral treatment,” with higher scores for 
patients that concluded therapy.  Conclusion: HRQoL was 
negatively affected in several domains in Portuguese pa-
tients with chronic hepatitis C; oral antiviral treatment cor-
related with better quality of life, assuring its benefits on this 
population; the CLDQ Portuguese version revealed ade-
quate psychometric properties, and was useful in assessing 
quality of life in Portuguese HCV patients.
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 Abstract 
 Introduction: Chronic hepatitis C virus (HCV) infection im-
pacts multiple health and psychosocial dimensions and en-
compasses a significant overall burden as it progresses to 
advanced stages of hepatic disease.  Aims: To evaluate for 
the first time health-related quality of life (HRQoL) of a subset 
of Portuguese adult patients with chronic hepatitis C using 
the Portuguese versions of generic, Short-Form 12 Health 
Survey (SF-12v2), and disease-specific, Chronic Liver Disease 
Questionnaire (CLDQ), instruments; to assess psychometric 
properties of CLDQ, Portuguese version.  Methods: HRQoL 
was evaluated in Portuguese adult outpatients with chronic 
hepatitis C attending the Hepatology Clinic at Centro Hospi-
talar do Porto, using SF-12v2 and CLDQ. This transversal 
study was conducted between April and October 2015.  Re-
sults: Eighty outpatients with chronic hepatitis C were en-
rolled, with mean age 57 years (standard deviation 11), 
67.5% male, all Caucasian, 76.3% diagnosed for >10 years, 
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 Qualidade de Vida Relacionada com a Saúde em 
Doentes Portugueses com Hepatite C Crónica 
 Palavras Chave 
 Hepatite C Crónica · Portugal · Psicometria · Qualidade 
de Vida · Questionários de Saúde 
 Resumo 
 Introdução: A infeção crónica por vírus da hepatite C (VHC) 
afeta múltiplas dimensões da saúde física e psicossocial e 
tem um impacto global significativo à medida que progride 
para estadios mais avançados de doença hepática crónica. 
Objetivos: Avaliar, pela primeira vez, a qualidade de vida re-
lacionada com a saúde (QdVS) em uma amostra de doentes 
portugueses, adultos, com hepatite C crónica, usando as 
versões Portuguesas de um instrumento genérico, Short-
Form 12 Health Survey (SF-12v2), e de um instrumento es-
pecífico da doença, Chronic Liver Disease Questionnaire 
(CLDQ); estudar as propriedades psicométricas da versão 
portuguesa do CLDQ. Métodos: Foi avaliada a QdVS de 
doentes adultos com hepatite C crónica seguidos em con-
sulta de Hepatologia no Centro Hospitalar do Porto, recor-
rendo às versões portuguesas dos instrumentos de qualida-
de de vida, SF-12v2 e CLDQ. Este estudo transversal decor-
reu entre Abril e Outubro de 2015. Resultados: Foram 
avaliados 80 doentes, 67.5% do sexo masculino, idade mé-
dia 57 ± 11 anos, 76.3% com infeção diagnosticada há mais 
de 10 anos, 66.3% Genótipo 1 VHC, 65.0% com cirrose hepá-
tica (94.2% destes Child-Pugh A), 46.3% sob terapêutica an-
tiviral oral atual e 12.5% com terapêutica já concluída. Como 
consistência interna obteve-se um  α-Cronbach de 0.88; as 
correlações de validade de constructo variaram entre 0.36–
0.80 ( p < 0.01). Os scores médios de qualidade de vida do 
CLDQ variaram entre 4.25 (‘Preocupação’) e 5.78 (‘Sintomas 
abdominais’). Obtiveram-se resultados inferiores nos domí-
nios ‘Preocupação’, ‘Fadiga’ e ‘Função emocional’. Na variá-
vel ‘terapêutica antiviral oral’ verificaram-se diferenças sig-
nificativas nos valores medianos dos domínios ‘Preocupa-
ção’/CLDQ e ‘Desempenho emocional’/SF-12 ( p < 0.05), com 
valores mais elevados para o subgrupo com terapêutica an-
tiviral já concluída. Conclusão: A QdVS revelou ser negativa-
mente influenciada nos doentes portugueses com hepatite 
C crónica; o tratamento antiviral oral associou-se a melhor 
qualidade de vida, reafirmando os seus benefícios nesta po-
pulação; a versão portuguesa do CLDQ revelou proprieda-
des psicométricas adequadas, sendo útil na avaliação da 
qualidade de vida em doentes portugueses com hepatite C 
crónica.  © 2016 Sociedade Portuguesa de Gastrenterologia
Publicado por S. Karger AG, Basel 
 Introduction 
 Hepatitis C virus (HCV) chronic infection constitutes 
a serious, well-recognized global public health issue, 
mainly due to the high rate of progression to advanced 
chronic liver disease (CLD) with significant morbidity 
and mortality. It impacts a range of dimensions that go 
far beyond each patient’s physical and psychosocial health 
and clinical management, extending to community and 
health policy settings  [1] .
 The true prevalence of hepatitis C in Portugal is un-
known, although in clinical practice hepatitis C is in-
creasing, being the most reported among viral hepatitis 
infections. An incidence of at least 1: 100,000 HCV infec-
tions and a prevalence between 1 and 1.5% are estimated 
in Portugal, yet with a diagnostic rate of 30%  [1] . The 
burden of the disease is appreciable, with Portugal being 
one of the European countries with higher rates of dis-
ability-adjusted life years (DALYs) associated with HCV 
(152.2 DALYs/100,000 persons). Also the financial im-
pact has been substantial and predominantly associated 
with complications of advanced hepatic disease  [1] . Bear-
ing epidemiological data on HCV infection, an increase 
is expectable in the reported chronicity, associated com-
plications, and overall burden of disease in forthcoming 
years  [1] .
 Assessment of health-related quality of life (HRQoL) 
has become a frequent and valuable outcome measure in 
clinical research with patients facing chronic diseases, in-
cluding CLD  [2–5] . This multidimensional concept refers 
to a patient’s subjective and dynamic assessment and per-
ception of his/her own state of health. It integrates physi-
cal, mental and social health-related contexts  [6] . It can 
influence therapeutic management and encourage pa-
tients to engage in the decision-making process  [4–7] .
 The progression of HCV infection to more advanced 
stages of hepatocellular dysfunction has proved to nega-
tively affect HRQoL, but this impact can be appreciable at 
any stage of severity  [5, 8–10] . The assessment of HRQoL 
in HCV patients might help to better understand the bur-
den of extrahepatic manifestations and treatment out-
comes, and thus provide improved support to these pa-
tients  [6] .
 The assessment of HRQoL comprises the use of ge-
neric or specific instruments. The generic, like the Short-
Form 36 Health Survey (SF-36) and Short-Form 12 
Health Survey (SF-12), are universally applied across dif-
ferent diseases and populations, allowing for compari-
sons  [6, 11] . The specific measures are more comprehen-
sive and focus on possible changes occurring in the course 
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of disease  [6, 11] . A particular specific instrument is the 
Chronic Liver Disease Questionnaire (CLDQ), developed 
by Younossi et al.  [8] . It is useful in all etiologies of liver 
disease at any severity stage  [2, 3] and appears to provide 
a valuable measure of HRQoL in CLD across different 
cultures  [2, 3, 12–15] .
 Combining both generic and disease-specific instru-
ments can provide additional evidence on HRQoL and 
thus a more comprehensive clinical approach  [2, 3] . The 
HRQoL of Portuguese patients with chronic HCV is 
largely unknown, although it is central to clinical man-
agement, promoting a more active enrollment and thera-
peutic compliance  [4, 5] .
 The aims of this study  were  to evaluate HRQoL in a 
subset of Portuguese adult patients with chronic HCV us-
ing the Portuguese versions of a generic (SF-12) and a 
disease-specific (CLDQ) instrument, and to assess the 
psychometric properties of the CLDQ Portuguese ver-
sion.
 Materials and Methods 
 Patients and Study Design 
 This study was conducted at the Hepatology Clinic, Hospital 
de Santo António (HSA), Centro Hospitalar do Porto (CHP), Por-
to, Portugal, between April and October 2015. It is a descriptive, 
clinical and epidemiological, observational transversal study. It 
was aimed at the population of adult outpatients with chronic 
HCV attending Hepatology Clinic at this referral center. Eligible 
patients were consecutive outpatients aged  ≥ 18 years old with the 
diagnosis of chronic HCV. Exclusion criteria were: co-infection 
with other hepatitis viruses or/and human immunodeficiency vi-
ruses; coexistence of other forms of hepatic disease (namely alco-
holic, autoimmune, or genetic/metabolic); a recent episode of de-
compensation of the liver disease (ascites, variceal hemorrhage, 
hepatic encephalopathy, or spontaneous bacterial peritonitis in the 
previous 6 months); extremely low literacy level or cognitive status 
precluding reliable participation.
 Patients were asked to complete 3 self-administered question-
naires during a regular outpatient visit, with an estimated response 
time of 10–20 min. A trained interviewer was available to assist 
patients as needed and to confirm full completion of question-
naires. All patients received oral and written explanation of the 
study and signed an informed consent form to participate after full 
clarification of the study’s aims and requirements. Privacy was re-
spected, and every patient was assured about the confidentiality of 
data. The study was reviewed and approved by the Hospital Ethical 
Committee, Research Coordinator Office, and authorized by the 
CHP Administration Board.
 Instrument Measures 
 The following self-administered instruments were used: a so-
ciodemographic and clinical data questionnaire and Portuguese 
versions of the SF-12 (generic) and CLDQ (disease specific) 
HRQoL questionnaires. The sociodemographic and clinical data 
are described in the next section. Some specifications of the HRQoL 
measures are presented in  Table 1 .
 The CLDQ is applicable to all etiologies and severity stages of 
CLD. CLDQ was translated and validated in several languages, and 
has been reported as a useful measure of HRQoL in clinical trials 
across different cultures  [2, 3, 8] .
 A written license agreement to use the certified Portuguese 
(Portugal) version of CLDQ was obtained by the first author from 
Dr. Zobair Younossi in December 2014. The translation and lin-
guistic validation process of CLDQ into the Portuguese (Portugal) 
language was previously undertaken in 2008 by PharmaQuest ® 
Ltd., following accurate methodology. As far as we are concerned, 
the CLDQ has not yet been validated in a Portuguese population. 
Although this study aimed to report some CLDQ psychometric 
properties, the validation of this measure in Portuguese HCV pa-
tients is beyond its scope.
 The SF-12 Health Survey was developed as a shorter alternative 
to the original SF-36, when the latter is considered too long and 
imposes a great burden on respondents. The SF-12 retains the 
comprehensiveness of the content and psychometric efficiency, 
particularly in large-scale studies focused on physical and mental 
health assessments  [16, 17] .
 The SF-36 Health Survey is a reliable and valid measure for as-
sessing domains of health status. It was considered by some au-
thors as the most appropriate generic HRQoL instrument for use 
in hepatology due to its psychometric properties  [13] . SF-36 was 
validated in the Portuguese language by Ferreira  [7, 18] . The SF-12 
is entirely a subset of the SF-36, covering the same 8 domains of 
health and correlating well with SF-36 summary scores, thus pro-
viding good reproduction of these  [16] .
 In our study, a trial with SF-36 was completed with the first 10 
eligible HCV patients. There was a lack of compliance due to the 
length of the questionnaire and associated fatigue. As we could not 
obtain valid responses, after this trial we adopted the shorter form 
SF-12, which improved compliance.
 The remaining clinical data were assessed from medical re-
cords, including: HCV genotype, severity of disease (cirrhosis and 
Child-Pugh score), indirect assessment of hepatic fibrosis (Fi-
broscan ® ); current antiviral therapy, type and duration; comor-
bidities.
 CLDQ Portuguese Version: Psychometric Properties 
 The following psychometric properties of the CLDQ Portu-
guese version were assessed: internal consistency, construct valid-
ity (convergent and discriminant), and floor or ceiling effects. In-
ternal consistency refers to the extent to which items in a domain 
are correlated, thus measuring the same concept. According to 
Terwee et al.  [19] a Cronbach’s α between 0.70 and 0.95 is consid-
ered an adequate measure of internal consistency. Convergent 
 validity measures the extent to which domains in an instrument 
 correlate with others that assess a similar concept, according to 
derived hypotheses  [19] . In accordance with previous work cor-
relating CLDQ with SF-12 domains  [12, 20] , we hypothesized high 
correlations ( r > 0.70) between: Fatigue (CLDQ) and Vitality (SF-
12); Activity (CLDQ) and Physical Functioning (SF-12); Emotion-
al Function (CLDQ) and Mental Health (SF-12)  [12, 20] . Discrim-
inant validity refers to the extent to which a measure does not cor-
relate too strongly with measures intended to assess different traits. 
We hypothesized low correlations ( r < 0.50) between the domains: 
Abdominal symptoms (CLDQ) and Role emotional (SF-12); Wor-
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ry (CLDQ), with Physical Functioning, Role Physical and Bodily 
pain (SF-12)  [12, 20] .
 If more than 15% of patients achieved the lowest or the highest 
possible score on CLDQ domains, floor and ceiling effects, respec-
tively, were considered to be present. They suggest missing items 
at the lower or upper end of the domain and thus limited content 
validity  [19] .
 For a qualitative analysis, we aimed to gather the patients’ per-
ception regarding easiness and relevance of the CLDQ Portuguese 
version. Patients were asked about overall opinion and whether 
any item was difficult to understand.
 HRQoL Assessment 
 Mean and standard deviation (SD) CLDQ scores were calcu-
lated.
 Several variables were analyzed for significant differences in 
median values of CLDQ and SF-12 domains (using the nonpara-
metric tests Mann Whitney U and Kruskal-Wallis;  p < 0.05), 
namely: gender, age group, stage of disease, time since diagnosis, 
current antiviral oral treatment, comorbidities (depression) and 
lifestyle variables (previous intravenous drug use; physical activi-
ty). Some of the hypotheses we derived were supported by previous 
studies: (a) male patients were expected to present better HRQoL 
scores, especially in the domains related to emotional traits and 
physical dimensions  [6, 12, 21] ; (b) younger patients were expect-
ed to present better HRQoL scores, and patients with longer time 
since diagnosis were expected to have lower HRQoL scores, espe-
cially on items related to physical symptoms and activity levels  [1, 
12, 22] ; (c) no significant differences were expected regarding stage 
of disease, as 94% of the patients with cirrhosis had compensated 
disease (Child-Pugh A)  [8, 13, 23] ; (d) patients with concluded an-
tiviral treatment were expected to have higher HRQoL scores  [24, 
25] ; (e) patients with depression were expected to have lower 
HRQoL scores, mainly on emotional traits  [4] ; (f) patients with 
previous intravenous drug use were expected to have lower HRQoL 
scores due to prevailing stigma  [6, 26] ; (g) patients practicing ex-
ercise were expected to present higher HRQoL scores on physical 
domains  [27, 28] .
 Statistical Analysis 
 Data were analyzed using Microsoft Office Excel 2013 and the 
IBM ® Statistical Package for Social Sciences for Windows-SPSS ® 
version 22.0. Distributions of continuous variables were analyzed, 
and Kolmogorov-Smirnov tests were performed to assess their de-
viation from a normal distribution. Quantitative variables were 
summarized as mean and SD, or as median and 25th and 75th 
quartiles for variables exhibiting skewed distributions. Such vari-
ables were compared using nonparametric tests. In order to allow 
for comparisons with other studies, some continuous variables 
were presented as mean and SD. The level of significance was set 
at  p < 0.05 or  p < 0.01.
 Table 1.  Specifications of the HRQOL measures used in the study [5, 16, 20]
Short-Form 12 Health Survey (SF-12v2) Chronic Liver Disease Questionnaire (CLDQ)
Type of measure Generic Disease specific
Self-administered Self-administered
Author Ware et al., 1996 [17] Younossi et al., 1999 [8]
Construction Entirely derived from SF-36 Original
No. of items 12 29
No. of subscales 8 (+2 summary scores) 6
Symptoms time frame Symptoms presented for the last 4 weeks Symptoms presented for the last 2 weeks
Subscales/domains Physical Function (PF); Role Physical (RP); Bodily Pain 
(BD); General Health (GH); Vitality (V); Social Function 
(SF); Role Emotion (RE); Mental Health (MH); Summary 
measures physical and mental component summary 
measures (PCS-12 and MCS-12)
Fatigue (perception of decreased energy, strength and 
sleepiness); Activity (eating habits and trouble lifting and 
carrying objects); Emotional Function (mood, concentration, 
sleep); Abdominal Symptoms (bloating, pain, discomfort); 
Systemic symptoms (bodily pain, muscle cramps, itching, 
dry mouth, shortness of breath); Worry (concerns regarding 
disease progression and impact on family) [12, 20]
Psychometric
properties
TRR: PCS r = 0.89; MCS r = 0.76 (US sample) [17]; 
cross-validation: PCS-36 and PCS-12 correlated 0.95; 
MCS-36 and the MCS-12 correlated 0.97 [16]
IC: α = 0.95 overall (α = 0.72 Activity to α = 0.92 Fatigue) [20]; 
TRR: r = 0.69 to r = 0.79 [20]; CV: worse CLDQ scores with 
increased disease severity [5]
Scoring and
interpretation
Items scored on a 100-point scale – higher score meaning 
better HRQoL; overall information is computed using 
specific algorithms to derive the 8 health domains and the 
summary scores PCS-12 and MCS-12
Items scored on a 7-point Likert scale; 1 – maximum frequency 
(“all of the time”) and 7 – minimum (“none of the time”); 
domain scores are the means of the items contained, and the 
overall score is the mean of all domains
 Higher score on each scale – minimum symptoms – higher HRQoL; lower scores – pronounced symptoms – lower HRQoL. IC, internal consistency; 
TRR, test-retest reliability; CV, construct validity; HRQoL, Health-Related Quality of Life.
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 Results 
 A total of 80 patients with chronic HCV were en-
rolled in the study, with a mean age of 57 years (SD 11), 
67.5% of which were male, all Caucasian, 76.3% with 
HCV diagnosed for longer than 10 years, 66.3% with 
HCV genotype 1, 65.0% with hepatic cirrhosis (94.2% of 
which Child-Pugh A), 46.3% under current antiviral 
treatment, and 12.5% with concluded treatment; 32.5% 
of patients had a history of past intravenous drug use 
and 25.0% had depressive syndrome. The detailed so-
ciodemographic, clinical, and lifestyle characteristics of 
the sample are presented in  Table 2 . Most patients read-
ily self-completed the questionnaires, but 14 patients re-
quired some assistance mainly due to uncorrected vi-
sual impairment.
 Table 2. Sociodemographic, clinical and lifestyle characteristics of HCV patients
Sociodemographic
Age, years 57 ± 11 (36 – 88)
Age groups
≥50 years 23 (28.8)
50 – 65 years 41 (51.3)
>65 years 16 (20.0)
Gender
Male 54 (67.5)
Female 26 (32.5)
Country of birth
Portugal 76 (95.0)
Race/ethnicity
Caucasian 80 (100)
Occupation
Employed 25 (31.3)
Unemployed 21 (26.3)
Retired (by disease) 21 (26.3)
Retired (by age) 13 (16.3)
Marital status
Single 18 (22.5)
Married 44 (55.0)
Divorced 14 (17.5)
Widow 4 (5.0)
Educational level
<4 years 3 (3.7)
Primary, 4 years 26 (32.5)
Up to high school, 5 – 11 years 39 (48.8)
Higher education, ≥14 years 12 (15.1)
Lifestyle
Currently smoking 30 (37.5)
Currently drinking 18 (22.5)
Previous iv drug use 26 (32.5)
Duration of drug use >5 years 17 (21.3) [65.4]
Exercise 20 (25.0)
2 – 3 times/week 13 (16.3) [65.0]
Clinical
Time since diagnosis 
1 – 10 years 19 (23.8)
10 – 20 years 35 (43.8)
20 years 26 (32.5)
HCV genotype
G1 (a or b) 53 (66.3)
G3 (a or b) 19 (23.8)
Other (G2 or G4) 5 (6.2)
Unknown 3 (3.8)
Hepatic fibrosis (Fibroscan)
F1 11 (13.8)
F2 11 (13.8)
F3 16 (20.0)
F4 35 (43.8)
Undetermined (F3 or F4) 6 (7.5)
Unknown 1 (1.3)
Severity of liver disease
No cirrhosis 28 (35.0)
Cirrhosis 52 (65.0)
Child-Pugh A 49 (61.3) [94.2]
Oral antiviral treatment
Ongoing 37 (46.3)
Already concluded 10 (12.5)
Not started 33 (41.3)
Duration of ongoing treatment
≤4 weeks 12 (15.0) [32.4]
4 – 12 weeks 19 (23.6) [51.4]
≥12 weeks 6 (7.5) [16.2]
Previous antiviral treatment 51 (63.8)
Comorbidities
Hypertension1 31 (38.8)
Diabetes mellitus1 11 (13.8)
Cardiovascular disease2 11 (13.8)
Renal transplantation 6 (7.5)
Hematologic disease3 6 (7.5)
Obesity and excess weight 12 (15.0)
Depression1 20 (25.0)
Anxiety1 20 (25.0)
Psychiatric disease1, 4 5 (6.3)
Results are presented as mean ± SD (range) for age and absolute and relative frequencies for other items (in the whole sample, n = 
80), and [within the subgroup]. HCV, hepatitis C virus. 1 Includes patients under therapy. 2 Cardiovascular disease diagnosed or with 
history of previous event. 3 Includes hemophilic patients and other coagulopathy. 4 Excluding depression.
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 Regarding the assessment of CLDQ’s psychometric 
properties, data on the internal consistency of the CLDQ 
scales are presented in  Table 3 . Mean Cronbach’s α was 
0.88, ranging from 0.68 to 0.89. For construct validity, 
some of the correlations between the CLDQ and SF-12 
domains are presented in  Table 4 . For convergent valid-
ity, correlations were all statistically significant, ranging 
from 0.36 to 0.80 ( p < 0.01), except those between Worry 
(CLDQ) and Vitality (SF-12) and between Abdominal 
Symptoms (CLDQ) and Social Functioning (SF-12). The 
highest correlations were found between: Emotional 
Function (CLDQ) and Mental Health (SF-12) ( r = 0.80, 
 p < 0.01); Fatigue (CLDQ) and Role Physical (SF-12) ( r = 
0.71,  p < 0.01); Fatigue (CLDQ) and Vitality (SF-12) ( r = 
0.70,  p < 0.01). For discriminant validity, correlations be-
tween scales hypothesized as less-comparable ranged be-
tween 0.25 and 0.42. These lowest correlations were found 
between: Worry (CLDQ) and Physical Functioning (SF-
12) ( r = 0.25,  p < 0.05); Worry (CLDQ) and Role Physical 
(SF-12) ( r = 0.26,  p < 0.05); Abdominal Symptoms 
(CLDQ) and Role Emotional (SF-12) ( r = 0.35,  p < 0.01). 
The proportion of floor effects (presented in  Table 3 ) was 
 Table 3. Distribution, reliability and floor and ceiling effects of the CLDQ Portuguese version domains
CLDQ Mean (SD) Median 25th 
quartile
75th 
quartile
Min. Max. Internal consistency 
(Cronbach α)
Floor1,
%
Ceiling1,
%
Fatigue 4.61 (1.58) 4.7 3.4 6.0 1 7 0.88 1.25 7.50
Emotional Function 4.69 (1.45) 4.9 3.8 5.8 1 7 0.89 3.75 5.00
Worry 4.25 (1.87) 4.2 2.7 6.0 1 7 0.88 2.50 11.25
Abdominal Symptoms 5.78 (1.52) 6.3 5.0 7.0 1 7 0.86 1.25 41.25
Activity 5.42 (1.57) 6.0 4.7 7.0 1 7 0.72 2.50 25.00
Systemic Symptoms 5.24 (1.17) 5.4 4.6 6.2 1 7 0.68 0.00 6.25
SD, standard deviation. 1 Proportion of patients with worse (“floor”, score: 1) and better (“ceiling”, score: 7) outcome of HRQoL 
(Health Related Quality of Life).
 Table 4. Statistically significant correlations of the CLDQ domains with SF-12 subscales for convergent and discriminant validity 
(Spearman rank-order correlation coefficient; p < 0.01)
 CLDQ
Fatigu e Emotional
Function
Worry Abdominal
Symptoms
Activity Systemic
Symptoms
CLDQ
Fatigue
Emotional Function 0.61
Worry 0.37 0.54
Abdominal Symptoms 0.40 0.46 0.50
Activity 0.73 0.56 0.53 0.52
Systemic Symptoms 0.63 0.63 0.54 0.69 0.66
SF-12
General Health
Physical Functioning
Role Physical 0.71 0.54
Role Emotional 0.63
Bodily Pain 0.55
Mental Health 0.66 0.80 0.50
Vitality 0.70 0.151
Social Functioning 0.201
1 The only correlations not statistically significant (p > 0.05).
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low and below the 15% criteria on every CLDQ domain. 
The proportion of ceiling effects was overall low, except 
for Abdominal Symptoms and Activity CLDQ domains 
(41.3 and 25.0%, respectively).
 Considering HRQoL, mean CLDQ scores for Portu-
guese HCV patients are presented in  Figure 1 . Mean 
scores ranged from 4.25 (Worry) to 5.78 (Abdominal 
Symptoms). The lower CLDQ scores pertain to Worry, 
Fatigue, and Emotional Function domains. The highest 
CLDQ scores refer to Abdominal Symptoms and Activity 
domains. In the analysis of HRQoL, where statistically 
significant differences in the median values of CLDQ do-
mains were considered ( Table 5 ), significant differences 
were not found in “gender,” “age group,” “stage of dis-
ease,” and “time since diagnosis” (all p > 0.05). In con-
trast, significant differences by “gender” were found in 
 Table 5. p values for significant differences between median values of CLDQ domains and SF-12 subscales (p < 0.05) and demographic, 
clinical, comorbidity, and lifestyle variables
Demographic Clinical Depression 
comorbidity
Lifestyle
gender age group stage of
disease
time since
diagnosis
current oral
treatment
previous iv
drug use
physical activity
CLDQ
F 0.04
EF 0.00
W 0.02 0.03
AS 0.02
A
SS 0.061 0.02
SF-12
GH 0.01
PF 0.03 0.04
RP 0.03 0.03 0.04
RE 0.04
BP 0.01 0.02 0.02
MH 0.02 0.091 0.01
V 0.01 0.02
SF 0.01 0.00
F, Fatigue; EF, Emotional Functioning; W, Worry; AS, Abdominal Symptoms; A, Activity; SS, Systemic Symptoms; GH, General 
Health; PF, Physical Functioning; RP, Role Physical; RE, Role Emotional; BD, Bodily Pain; MH, Mental Health; V, Vitality; SF, Social 
Functioning. 1 Not statistically significant differences in median values (p > 0.05).
Fatigue
1
2
3
4
5
6
7
8
M
ea
n 
an
d 
SD
 C
LD
Q
 s
co
re
s 
fo
r 
th
e 
Po
rt
ug
ue
se
 H
CV
 p
at
ie
nt
s
Emotional
Function
Worry Abdominal
Symptoms
Activity Systemic
Symptoms
 Fig. 1. Mean and SD CLDQ scores for the 
Portuguese HCV patients. The lower scores 
for the Portuguese sample were observed 
for CLDQ domains Worry, Fatigue, and 
Emotional Function. Value 1 indicates 
poorest HRQoL; 7 indicates best HRQoL. 
HCV, hepatitis C virus. 
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the median values of Physical Functioning, Role Physical, 
Mental Health, and Vitality (SF-12), with highest values 
(meaning better HRQoL) in males ( p < 0.05). Statistically 
significant differences by “age group” were also found in 
median values of General Health, Physical Functioning, 
Role Physical, Bodily pain and Social Functioning (SF-
12), with highest values (better HRQoL) in age group  ≤ 50 
years. For “time since diagnosis,” significant differences 
were found in the median values of Bodily Pain (SF-12), 
with significantly lower value (indicating worse HRQoL) 
for the subgroup with >20 years since diagnosis (p < 0.05). 
For “stage of disease,” statistically significant differences 
were not found in the median values of neither domain, 
although there was a tendency towards significant differ-
ences in Systemic Symptoms (CLDQ) and Mental Health 
(SF-12). In “current antiviral oral treatment,” statistically 
significant differences were found in median values both 
for Worry (CLDQ) and Role Emotional (SF-12), with sig-
nificantly higher values (indicating better HRQoL) for 
the subgroup that already concluded therapy. Significant 
differences were still found for Worry (CLDQ) when 
comparing patients admitted to treatment (ongoing or 
already concluded) with those without treatment, with 
higher HRQoL scores for the former. For “depression,” 
statistically significant differences were found in the me-
dian values of Emotional Functioning, Systemic Symp-
toms, and Fatigue (CLDQ) and Mental Health, Bodily 
Pain, Role Physical and Social Functioning (SF-12), with 
significant lower values (indicating worse HRQoL) for 
the subgroup with depression. For “previous intravenous 
drugs use,” statistically significant differences were found 
in median values of Worry (CLDQ), with significant low-
er scores for patients with past intravenous drug use. For 
“physical activity,” significant differences were observed 
in the median values of Abdominal Symptoms (CLDQ) 
and Vitality (SF-12), with significant higher scores for pa-
tients engaging physical activity.
 Most patients found the CLDQ easy to understand and 
relevant. Two patients referred the relevance of an item 
covering “apathy” (meaning “lack of concern/interest”). 
The last item, regarding concern about availability of a 
liver transplant if needed, was described as “overstated” 
by some patients.
 Discussion and Conclusions 
 Chronic HCV infection remains a global health con-
cern, with multiple and significant impact associated with 
disease progression  [1, 4] . In Portugal, the overall burden 
of HCV is appreciable and is expected to rise in forthcom-
ing years  [1] . Assessment of HRQOL combining general 
and disease-specific instruments is lacking in Portuguese 
HCV patients, thus being the main goal of this study.
 The assessed CLDQ’s psychometric properties were 
overall adequate. Namely, for internal consistency, mean 
Cronbach’s α fitted the defined criteria  [19] , which was 
consistent with reports from the original CLDQ  [8, 20] 
and European CLDQ validation studies  [12, 13] . Retest 
reliability was not assessed, which should be regarded as 
a limitation of this study.
 Most of the hypothesized correlations for convergent 
and discriminant validity  [20] were confirmed. As pre-
dicted, we found high correlations ( r > 0.70) between 
CLDQ and SF-12 domains assumed to measure a similar 
concept. The Activity (CLDQ) and Physical Functioning 
(SF-12) domains were only moderately correlated, but we 
found instead high correlation with Role Physical (SF-
12). As all of these domains reasonably assess limited ac-
complishments in activities  [17] , they are strongly corre-
lated. For discriminant validity, as predicted  [20] we 
found low correlations ( r < 0.50) between: Worry (CLDQ) 
and Physical Functioning (SF-12); Worry (CLDQ) and 
Role Physical (SF-12). These expectedly assess different 
traits: Physical Functioning and Role Physical explored 
levels of difficulty and limitations in physical activities or 
diminished activity accomplishments, respectively. In 
contrast, Worry involved concerns about developing 
more severe and progressive symptoms and the impact 
on family  [17, 20] . We also found lower correlations in 
Abdominal Symptoms (CLDQ) and Role Emotional (SF-
12) domains, as the former assessed presence of abdomi-
nal bloating, discomfort or pain, and the latter involved 
interference of emotional issues  [17, 20] .
 The presence of moderate to low correlations between 
some CLDQ and SF-12 domains is valuable and suggests 
that CLDQ provided additional relevant HRQoL infor-
mation concerning HCV patients not covered by generic 
instruments such as SF-12  [12, 13] .
 The percentages of floor and ceiling effects in CLDQ 
domains were reasonably adequate  [19] . The ceiling ef-
fect on the Activity domain was also found in a previous 
study  [12] , suggesting that extreme items (regarding bet-
ter symptoms) might be missing to better discriminate 
patients.
 Considering HRQoL assessed by CLDQ, our sample of 
Portuguese HCV patients revealed lower levels of HRQoL 
in the Fatigue, Worry, and Emotional Function domains. 
As fatigue represents one of the most frequent and dis-
abling features in CLD and HCV  [29, 30] , low levels were 
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an expected outcome. Accordingly, previous studies 
point fatigue as an independent predictor of low HRQoL 
 [4] . Disease-related worries have been claimed as having 
an impact on HRQoL of HCV patients  [31] . Also, the 
strong perceived stigma associated with this infection can 
affect self-esteem, social functioning and raise uncertain-
ty and increased concerns about the future and disease 
progression  [32, 33] . These might explain the low HRQoL 
levels in CLDQ Worry domain. The outcome on Emo-
tional Function might be related to the presence of diag-
nosed depression and anxiety (in 25.0% of the patients 
each). The significant overlap of depressive or anxiety 
syndromes in this population is widely reported  [4, 29, 
34] . Depression was documented in 28.0% of HCV-naïve 
patients  [34] , and anxiety in 24.0% of HCV patients  [4] , 
which closely resembled the proportion found in our 
sample. Depression in these patients is associated with 
higher levels of subjective physical symptoms, higher 
stigma, and lower coping strategies  [34] , and thus with 
lower HRQoL  [4, 35] . As expected, significant worse 
HRQoL was found for depressed patients on Emotional 
Functioning, Systemic Symptoms, and Fatigue (CLDQ) 
and in several SF-12 subscales.
 In contrast, better HRQoL scores were found in Ab-
dominal Symptoms and Activity domains, which could 
relate to sample characteristics. Thirty-five percent of pa-
tients did not have cirrhosis, and considering the cirrhot-
ic patients, 94.2% had compensated disease. Following 
the natural history of CLD, patients may remain mild 
symptomatic for a long course or have unspecific com-
plaints  [6, 22] . Eventually compensated patients could re-
port less abdominal symptoms and higher activity indi-
ces, compared with patients with decompensated disease.
 From the variables compared for statistically signifi-
cant differences regarding CLDQ and SF-12 domains, 
most of the hypotheses were corroborated. Better HRQoL 
was found for male gender in some SF-12 subscales, like 
in some previous studies  [6, 12] . In accordance, a Portu-
guese study on the definition of SF-36 Portuguese norms 
 [21] concluded that the female gender independently cor-
related significantly with lower (meaning worse) self-per-
ception of health state.
 The outcome of better HRQoL in the younger age 
group ( ≤ 50 years) and with less time since diagnosis 
could be explained by the CLD natural history; these 
groups were expected to be less symptomatic, to have 
fewer complications and a better HRQoL. Patients with 
longer diagnosis are more prone to more advanced and 
symptomatic disease (thus the significant difference in 
Bodily Pain subscale scores)  [1, 22] .
 As expected, we found no significant differences in the 
median values of CLDQ or SF-12 domains regarding “stage 
of disease.” This outcome is consistent with other studies 
 [12, 13] , where significant differences were only found 
when comparing patients with more advanced liver disease 
(Child-Pugh B and C). In our study, 35.0% of patients did 
not have cirrhosis, and from those who developed cirrho-
sis, 94.2% had compensated disease (Child-Pugh A).
 Considering the variable “current antiviral oral treat-
ment,” significantly better HRQoL was found on Worry 
(CLDQ) and Role Emotional (SF-12) in patients that al-
ready concluded antiviral treatment. This suggests that 
this subgroup became less concerned about the severity 
of symptoms and disease progression, probably due to the 
reduced symptoms and the confidence geared by an ef-
fective treatment. In this subgroup 6 patients were female, 
6 were aged 50–65 years, all but 1 with <20 years since 
diagnosis and none with previous EV drug use. Six pa-
tients had cirrhosis and 8 concluded 24 weeks of therapy. 
This is a particularly relevant outcome, as it shows that 
oral antiviral treatment can be correlated with HRQoL 
increases, particularly on domains among those who 
scored lower for our Portuguese patients. Recent studies 
on the impact of treatment with direct antiviral agents 
corroborate this evidence  [24, 25, 36] .
 Previous drug use is associated with higher stigma, and 
thus the levels of HRQoL can decrease, especially on do-
mains relating to concerns for disease and for the future 
 [32, 33] ; physical activity has been claimed to increase the 
scores in HRQoL physical domains and thus is recom-
mended  [27, 28] .
 The Portuguese CLDQ version demonstrated good ac-
ceptability and ease of administration. The adequacy of 
the last item was already discussed in a study with HCV 
patients  [14] , where it was omitted for not reflecting a 
predominant concern for this population. However, as 
the CLDQ integrates all severity CLD stages, it should in-
clude concern about treatment for end-stage disease, 
even though it lacks sensitivity for compensated disease.
 The relevance of this study should be emphasized, as 
it aimed to characterize HRQoL in Portuguese HCV pa-
tients and surpass the limited knowledge regarding health 
perception in this population. Combining generic and 
disease-specific instruments was intended to provide a 
more accurate assessment, and the presence of moderate 
to low correlations between some CLDQ and SF-12 do-
mains emphasized such complementarity. The CLDQ is 
becoming an increasingly useful instrument in this set-
ting, confirmed by its widespread use across different cul-
tures and properly validated versions. As the CLQD was 
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not yet validated in Portuguese, this study also aimed to 
build knowledge on some psychometric properties of the 
Portuguese version.
 Some limitations of this study should also be noted. 
Regarding methodology, adopting SF-12 might have 
compromised psychometric efficiency, particularly in the 
absence of a large-scale study with focus on physical and 
mental health summary scores. However, for our pur-
pose, it was more useful to derive the 8 health SF-36 sub-
scales to gather more detailed clinical data for meaningful 
comparisons. Another limitation pertained to the presen-
tation of continuous data from skewed distributions as 
mean and SD to allow for comparisons with similar stud-
ies. The tradeoff is that cautious assumptions should be 
drawn from these comparisons. Considering sample 
characteristics, it would be better to have a larger sample 
size and more balanced subgroups with an equivalent 
size, namely for gender, stage of disease, and current 
treatment variables. Our sample mainly included patients 
without cirrhosis or with compensated disease, which 
precluded analysis regarding the impact of more severe 
disease on HRQoL. Following previous studies, we fo-
cused on demographic and clinical variables that could 
relate to and explain differences in HRQoL in this popu-
lation. Bearing the effect of treatment on HRQoL, it 
would have been preferable to apply the questionnaires to 
the same patients before, during, and after oral antiviral 
therapy, to enable paired tests. Perhaps the most clear-cut 
limitation is the inability to objectively compare HRQoL 
scores due to the absence of standardized norms. It pre-
cludes a more objective definition of acceptable HRQoL 
scores and extent of HRQoL deviations for this popula-
tion. Further studies are clearly needed to better under-
stand the impact of HCV on HRQoL, to validate the 
CLDQ Portuguese version and to build standardized 
norms for the Portuguese population.
 Finally, we can conclude that HRQoL, as assessed by 
CLDQ and SF-12, was negatively affected in several do-
mains in Portuguese HCV patients, in line with previous 
findings. Some particular outcomes stand out from our 
study. The fact that oral antiviral treatment could be cor-
related with HRQoL increases in some domains provides 
growing evidence for the multiple benefits of appropriate-
ly treating these patients. Due to the high prevalence and 
negative impact of mood disorders (namely depression) on 
HRQoL, it might be valuable to screen and provide suitable 
psychosocial interventions in a multidisciplinary setting. 
The CLDQ Portuguese version revealed adequate psycho-
metric properties and good acceptability, being a useful in-
strument to assess HRQoL in Portuguese HCV patients.
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